Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development

Published 21/05/2024, 13:24
© Reuters.  ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
MSFT
-
SNY
-
MRNA
-

Benzinga - by Vandana Singh, Benzinga Editor.

Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects.

Also Read: Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings.

Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources.

The three teams will combine data, software, and tuned models to develop custom, purpose-built solutions for the drug development lifecycle.

OpenAI will contribute access to AI capabilities, including the ability to fine-tune models, deep AI expertise, and dedicated thought partnerships and resources.

Formation Bio, an AI and tech-driven drug developer with its pipeline of drug assets, will provide engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop, and deploy AI technologies across all aspects of the pharma lifecycle.

The potential benefits of AI for patients awaiting new treatments are immense, and Sanofi, Formation Bio, and OpenAI aim to set the standard for drug developers.

Last month, Moderna Inc (NASDAQ:MRNA) and Microsoft Corp (NASDAQ:MSFT)-backed OpenAI announced their ongoing collaboration to co-innovate.

Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna’s own instance of ChatGPT, called mChat. The company announced Wednesday that it has reached more than 80% internal adoption of mChat, which has accelerated the AI culture at Moderna.

Read Next: Sanofi’s Multiple Sclerosis Antibody Shows Reduction Of Disease Activity.

Price Action: SNY shares are down 0.62% at $48.12 during the premarket session at last check Tuesday.

Photo via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.